Drug Database
Back to search

Netherlands· NL-3857db0b0c66

ellaOne, 30 mg tabletten

A ulipristal product containing ulipristalacetaat, registered in Netherlands by Laboratoire HRA Pharma. The same ATC class is registered in 11 of our 19 countries.

ATC G03AD02

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedellaOne, 30 mg tablettenATCG03AD02REGISTER NO.NL-3857db0b0c66PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ulipristalacetaatAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ulipristal is registered in 11 of 19 countries.

Countries holding a registration under ATC G03AD02 (ulipristal), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 7 of them publish a price we can compare per daily dose
Search ulipristal products by name

Ulipristal · ATC G03AD02

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
ULIPRISTALACETAAT
Manufacturer
Laboratoire HRA Pharma
Country
Netherlands (NL)
ATC code
G03AD02
ATC class
Ulipristal
Defined daily dose
30 mg, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/09/522

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

98 interactions on record for ulipristal.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check ulipristal against other medicinesHow interaction checks work

Ulipristal · interactions on record

98 records

  • 2 severe
  • 77 moderate
  • 19 minor

Most severe, free to view

  • EdoxabanB01AF03severe
  • VenetoclaxL01XX52severe
  • NaldemedineA06AH05moderate
  • RifaximinA07AA11moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ulipristal in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ulipristal products

Authorised across Europe · EMA

The same active substance is authorised in 18 EEA countries. Names it is sold under:

  • Austria · Lencya, Ulipristal Acetate Hexal
  • Czechia · Ulipristal Acetate Aristo
  • Germany · Femke, Lencya
  • Denmark · Femke, Ulipristal Acetate Stada
  • Spain · Ulipristal Aristo, Ulipristal Aurovitas
  • Finland · Femke, Ulipristal Acetate Stada
  • France · Ulipristal Acetate Biogaran, Ulipristal Acétate Exeltis
  • United Kingdom (Northern Ireland) · Contrella, Ellaone
  • Greece · Boled, Elperil
  • Ireland · Ulipristal Acetate Rowex
  • Iceland · Ellaone, Ulipristal Acetate Stada
  • Italy · Evante, Lencya
  • Liechtenstein · Ellaone
  • Malta · Ecinq
  • Norway · Ellaone, Femke
  • Poland · Misstala, Ulipristal Aristo
  • Portugal · Femke, Ulipristal Aristo
  • Sweden · Ulipristal Acetate Stada

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9715fa08-77f1-4fb9-adc9-5a0b7f357dc5
GET /v1/drugs/9715fa08-77f1-4fb9-adc9-5a0b7f357dc5?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/ellaone-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Ulipristal",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp102807",
  "excipients": [
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "LACTOSE 1-WATER",
    "MAGNESIUMSTEARAAT (E 470b)",
    "POVIDON K 30 (E 1201)"
  ],
  "substances": [
    "ULIPRISTALACETAAT"
  ],
  "leaflet_url": null,
  "authorised_at": "2009/05/15",
  "procedure_number": "EMEA/H/C/001027",
  "dispensing_status": "Uitsluitend apotheek of drogist",
  "registration_number": "EU/1/09/522",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about ulipristal.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console